| 产品编号 | BH0003 |
| 英文名称 | Mouse Anti-Cytokeratin 19(ready to use) antibody |
| 中文名称 | 人细胞角蛋白19单克隆抗体（工作液） |
| 别 名 | 40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_HUMAN; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd |
| 研究领域 | 肿瘤 细胞生物 干细胞 |
| 抗体来源 | Mouse |
| 克隆类型 | Monoclonal |
| 克 隆 号 | 10H7 |
| 交叉反应 | Human |
| 产品应用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 40kDa |
| 细胞定位 | 细胞浆 细胞膜 |
| 性 状 | Liquid |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Cytokeratin 19 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M PBS (pH7.4) with 1% BSA and 0.02% Proclin300. |
| 保存条件 | Store at 2-8℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Due to its high sensitivity, KRT19 is the most used marker for the RT-PCR-mediated detection of tumor cells disseminated in lymph nodes, peripheral blood, and bone marrow of breast cancer patients. Depending on the assays, KRT19 has been shown to be both a specific and a non-specific marker. False positivity in such KRT19 RT-PCR studies include: illegitimate transcription (expression of small amounts of KRT19 mRNA by tissues in which it has no real physiological role), haematological disorders (KRT19 induction in peripheral blood cells by cytokines and growth factors, which circulate at higher concentrations in inflammatory conditions and neutropenia), the presence of pseudogenes (two KRT19 pseudogenes, KRT19a and KRT19b, have been identified, which have significant sequence homology to KRT19 mRNA. Moreover, Ck-19 is widely applied as post-operative diagnostic marker of papillary thyroid carcinoma. Function: Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. Subunit: Heterotetramer of two type I and two type II keratins. Interacts with PNN and the actin-binding domain of DMD. Interacts with HCV core protein. Tissue Specificity: Expressed in a defined zone of basal keratinocytes in the deep outer root sheath of hair follicles. Also observed in sweat gland and mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, ectocervical epithelium (at protein level). Expressed in epidermal basal cells, in nipple epidermis and a defined region of the hair follicle. Also seen in a subset of vascular wall cells in both the veins and artery of human umbilical cord, and in umbilical cord vascular smooth muscle. Observed in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma in structures that contain dystrophin and spectrin. Similarity: Belongs to the intermediate filament family. SWISS: P08727 Gene ID: 3880 Database links: Entrez Gene: 3880 Human Omim: 148020 Human SwissProt: P08727 Human Unigene: 654568 Human |
| 产品图片 |
Paraformaldehyde-fixed, paraffin embedded (human pancreatic carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 19) Monoclonal Antibody, Unconjugated (BH0003) overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 19) Monoclonal Antibody, Unconjugated (BH0003) overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 19) Monoclonal Antibody, Unconjugated (BH0003) overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human gastric carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 19) Monoclonal Antibody, Unconjugated (BH0003) overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Human breast); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 19) Monoclonal Antibody, Unconjugated (BH0003) overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human tonsil); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 19) Monoclonal Antibody, Unconjugated (BH0003) overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructionsand DAB staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
